Special Issues
Table of Content

Advances in Cancer Pharmacology

Submission Deadline: 30 June 2025 (closed) View: 1338 Submit to Journal

Guest Editors

Prof. Ning Wei

Email: ning.wei@einsteinmed.edu

Affiliation: Department of Oncology (Medical Oncology), Albert Einstein College of Medicine, Bronx, NY 10461, USA

Homepage:

Research Interests: Cancer Pharmacology&Drug Discovery


Prof. Giuseppe Nocentini

Email: giuseppe.nocentini@unipg.it

Affiliation: Department of Medicine, University of Perugia, 06129 Perugia, Italy

Homepage:

Research Interests: Pharmacology, Immunotoxicology, Pharmacoimmunology, Oncopharmacology


Summary

Advances in cancer pharmacology continue to transform the landscape of oncology by driving innovative therapies that target specific molecular mechanisms of cancer progression. This special issue aims to bring together cutting-edge research focused on the pharmacological treatment of cancer, with an emphasis on novel drug development, resistance mechanisms, and the optimization of therapeutic regimens.


Submissions are encouraged across a broad spectrum of topics, including but not limited to:

Targeted therapies and precision medicine approaches

Mechanisms of drug resistance in cancer treatment

Pharmacokinetics and pharmacodynamics of anticancer drugs

Combination therapies and their synergistic effects

Development of novel small molecules, biologics, and immunotherapies

Preclinical and clinical pharmacology studies

Drug repurposing for cancer treatment

Toxicity, safety, and quality of life considerations in cancer pharmacotherapy


We welcome original research articles, reviews, and clinical studies that explore innovative solutions to challenges in cancer pharmacology, with the goal of improving patient outcomes and advancing the field of oncology.


Keywords

Targeted Therapy, Drug Resistance, Immunopharmacology, Novel Anticancer Agents

Published Papers


  • Open Access

    ARTICLE

    Pyrimethamine Inhibits Human Ovarian Cancer by Triggering Lethal Mitophagy via Activating the p38/JNK/ERK Pathway

    Lingjuan Linghu, Hongying Zhou, Gang Zheng, Tao Yi
    Oncology Research, Vol.33, No.9, pp. 2421-2434, 2025, DOI:10.32604/or.2025.063724
    (This article belongs to the Special Issue: Advances in Cancer Pharmacology)
    Abstract Objectives: Ovarian cancer, a leading cause of gynecological malignancy-related mortality, is characterized by limited therapeutic options and a poor prognosis. Although pyrimethamine has emerged as a promising candidate demonstrating efficacy in treating various tumors, the precise mechanisms of its antitumor effects remain obscure. This study was specifically designed to investigate the mode of action underlying the antitumor effects of pyrimethamine in preclinical settings. Methods: The effects of pyrimethamine on cellular proliferation were meticulously assessed using both the cell counting kit 8 (CCK-8) assay and the colony formation assay, with the effects further confirmed in a… More >

  • Open Access

    ARTICLE

    Rare Primary Diffuse Large B-Cell Lymphoma Confined to Bone Marrow: Features and Prognosis

    Weiwei Chen, Xiaodie Zhou, Huiyu Li, Yuchen Yang, Lu Lu, Chunyan Zhu, Rong Fang, Xiaoyuan Chu, Shuping Zhou, Qian Sun
    Oncology Research, Vol.33, No.8, pp. 2123-2139, 2025, DOI:10.32604/or.2025.063484
    (This article belongs to the Special Issue: Advances in Cancer Pharmacology)
    Abstract Background: Primary bone marrow diffuse large B-cell lymphoma (PBM-DLBCL) represents an uncommon yet clinically aggressive hematologic malignancy. Despite its significant clinical impact, this entity lacks standardized diagnostic criteria in current WHO classifications. Methods: We performed a retrospective analysis of 55 PBM-DLBCL cases from our institutional database and published literature (2001–2022) to characterize disease features and identify prognostic factors, with particular focus on assessing how different treatment regimens influence therapeutic efficacy and long-term outcomes. Results: The data suggested a potential link between international prognostic index (IPI) scores and poorer survival, albeit without conclusive statistical evidence (p = More >

  • Open Access

    ARTICLE

    Synergistic anticancer and antibacterial effects of novel regimens of phytopolyphenols and repurposing drugs on cultured cells

    YA-LING YEH, YING-JAN WANG, SHOEI-YN LIN-SHIAU
    Oncology Research, Vol.33, No.7, pp. 1781-1796, 2025, DOI:10.32604/or.2025.063717
    (This article belongs to the Special Issue: Advances in Cancer Pharmacology)
    Abstract Background: The increasing incidence of cancers and infectious diseases worldwide presents a significant public health challenge that requires immediate intervention. Our strategy to tackle this issue involves the development of pharmaceutical formulations that combine phytopolyphenols (P), targeted drugs (T), and metal ions (M), collectively referred to as PTM regimens. The diverse pharmacological properties of PTM regimens are hypothesized to effectively reduce the risk factors associated with both cancers and infectious diseases. Methods: The effects of the pharmaceutical agents on the proliferation of cultured cancer cells and pathogens were assessed after 72 h and 48 h,… More >

  • Open Access

    REVIEW

    Unlocking the potential of tumor-targeting peptides in precision oncology

    HAFIZ MUHAMMAD REHMAN, SIDRA AHMAD, AZEEM SARWAR, HAMID BASHIR
    Oncology Research, Vol.33, No.7, pp. 1547-1570, 2025, DOI:10.32604/or.2025.062197
    (This article belongs to the Special Issue: Advances in Cancer Pharmacology)
    Abstract Targeted cancer therapy has emerged as a promising alternative to conventional chemotherapy, which is often plagued by poor selectivity, off-target effects, and drug resistance. Among the various targeting agents in development, peptides stand out for their unique advantages, including minimal immunogenicity, high tissue penetration, and ease of modification. Their small size, specificity, and flexibility allow them to target cancer cells while minimizing damage to healthy tissue selectively. Peptide-based therapies have shown great potential in enhancing the efficacy of drug delivery, improving tumor imaging, and reducing adverse effects. With cancer responsible for millions of deaths worldwide,… More >

Share Link